Drugs for Glaucoma 3, Primary Congenital, a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 22)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bevacizumab |
Approved, Investigational |
Phase 4 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
2 |
|
Angiogenesis Inhibitors |
|
Phase 4 |
|
|
|
3 |
|
Antineoplastic Agents, Immunological |
|
Phase 4 |
|
|
|
4 |
|
Travoprost |
Approved |
Phase 3 |
|
157283-68-6 |
5282226 |
Synonyms:
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(+)-Fluprostenol isopropyl ester
(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
157283-68-6
5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
AC1NQZOS
AC-6103
AL6221
AL-6221
C26H35F3O6
CHEBI:746859
CHEMBL1200799
CID5282226
D01964
DB00287
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
|
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
LS-173521
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
S1554_Selleck
Travatan
Travatan (TN)
Travatan Alcon
Travatan Z
Travatan, Travoprost
Travatanz
Travoprost
Travoprost (JAN/USAN/INN)
Travoprost [USAN]
Travoprostum
Z, Travatan
ZINC04474682
|
|
5 |
|
tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
6 |
|
Timolol |
Approved |
Phase 3 |
|
26839-75-8 |
5478 33624 |
Synonyms:
(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-timolol
131628-37-0
194288-09-0
26839-75-8
26921-17-5 (maleate (1:1) salt)
AB00513729
AC1L1PYN
AC1Q59QM
Apo-Timol
Apo-Timop
Aquanil
Betim
Betimol
Betimol (TN)
BIDD:GT0073
Blocadren
BPBio1_001008
BRD-K08806317-050-03-6
BSPBio_000916
C07141
C13H24N4O3S
CAS-26921-17-5
CHEBI:9599
CHEMBL499
CID33624
CPD001456519
D08600
DB00373
DB08625
EINECS 248-032-6
HMS2089I11
HSDB 6533
Istalol
L-714,465
Lopac0_001189
Lopac-T-6394
LS-122231
MK-950
NCGC00016038-01
NCGC00016038-02
|
NCGC00016798-01
NCGC00016798-07
NCGC00022033-02
NCGC00022033-04
NCGC00022033-05
Novo-Timol
Nu-Timolol
Oprea1_640981
Optimol
Phoxal-timolol
Prestwick0_000948
Prestwick1_000948
Prestwick2_000948
Prestwick3_000948
Proflax
S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole
S(-)-Timolol maleate
SAM002564238
SPBio_003075
ST072193
Temserin
Tenopt
TIM
Timacar
Timacor
Tim-AK
timolol
Timolol
Timolol (INN)
Timolol (TN)
Timolol [USAN]
Timolol anhydrous
Timolol GFS
Timolol maleate
Timolol Maleate, (1:1) Salt
Timololo
Timololum
Timololum [INN-Latin]
Timopic
Timoptic
Timoptic in Ocudose
Timoptic OcuDose
Timoptic-XE
Timoptol
Tocris-0649
UNII-817W3C6175
|
|
7 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
94-09-7, 1994-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
|
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
8 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 498142 |
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
9 |
|
Topotecan |
Approved, Investigational |
Phase 3 |
|
123948-87-8, 119413-54-6 |
60700 |
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
123948-87-8
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
Hydrochloride, nogitecan
Hydrochloride, topotecan
LS-127395
MLS000759456
NCGC00178695-01
NChemBio.2007.10-comp24
|
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
Nogitecan hydrochloride
NSC609699
SK And F 104864 a
SK And F104864a
SK And F-104864-a
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SmithKline beecham brand OF topotecan hydrochloride
SMP2_000312
SMP2_000327
SMR000466344
TOPO
topotecan
Topotecan
Topotecan (BAN)
Topotecan [INN:BAN]
Topotecan Hcl
Topotecan hydrochloride
Topotecan Hydrochloride
Topotecan lactone
Topotecan Lactone
Topotecan monohydrochloride, (S)-isomer
Topotecan Monohydrochloride, (S)-Isomer
TOPOTECAN, HYCAMTIN
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
UNII-7M7YKX2N15
|
|
10 |
|
Adrenergic beta-Antagonists |
|
Phase 3 |
|
|
|
11 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
12 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
13 |
|
Ophthalmic Solutions |
|
Phase 3 |
|
|
|
14 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
15 |
|
Anti-Arrhythmia Agents |
|
Phase 3 |
|
|
|
16 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
17 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
18 |
|
topoisomerase I inhibitors |
|
Phase 3 |
|
|
|
19 |
|
Alkylating Agents |
|
|
|
|
|
20 |
|
Anti-Bacterial Agents |
|
|
|
|
|
21 |
|
Antibiotics, Antitubercular |
|
|
|
|
|
22 |
|
Mitomycins |
|
|
|
|
|
Interventional clinical trials:
(show all 20)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma: a Randomized Clinical Trial. |
Unknown status |
NCT01494974 |
Phase 4 |
|
2 |
Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled Trial |
Completed |
NCT01166594 |
Phase 4 |
Bevacizumab;Control |
3 |
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients |
Completed |
NCT01652664 |
Phase 3 |
Travoprost 0.004% PQ ophthalmic solution;Timolol, 0.5% or 0.25% ophthalmic solution;Travoprost Vehicle |
4 |
GALOP II Protocol for the Treatment of Unilateral Retinoblastoma |
Recruiting |
NCT03475121 |
Phase 3 |
|
5 |
Comparative Evaluation of Combined Trabeculotomy-trabeculectomy Versus Combined Trabeculotomy-trabeculectomy With Subconjunctival Implantation of Collagen Matrix Implant for Primary Congenital Glaucoma. |
Unknown status |
NCT02121171 |
Phase 1 |
|
6 |
Comparison Between The Outcome of Deep Sclerectomy and Traditional Trabeculotomy and Trabeculectomy Surgeries in Congenital Glaucoma |
Unknown status |
NCT01460017 |
Phase 1 |
|
7 |
Genetic Testing in Primary Congenital Glaucoma Patients |
Unknown status |
NCT01136460 |
|
|
8 |
Study of Gene, Inheritance Pattern and Genotype - Phenotype Correlations in South Korean Patients With Primary Congenital Glaucoma |
Unknown status |
NCT01020721 |
|
|
9 |
Randomized Controlled Study to Evaluate Safety and Efficacy of Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy |
Unknown status |
NCT03541551 |
|
|
10 |
National Taiwan University Hospital |
Unknown status |
NCT00155857 |
|
|
11 |
Histopathological Examination of Iris Tissue in Buphthalmos |
Completed |
NCT04011878 |
|
|
12 |
Microcatheter Assisted Circumferential Trabeculotomy in Congenital Glaucoma |
Completed |
NCT04116450 |
|
|
13 |
A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) |
Completed |
NCT02945176 |
|
|
14 |
Endoscopic Goniotomy for Infantile Glaucoma |
Completed |
NCT00338533 |
|
|
15 |
Segregation/Linkage Analysis for Hypertension |
Completed |
NCT00005158 |
|
|
16 |
Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France |
Recruiting |
NCT03077789 |
|
|
17 |
INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register |
Recruiting |
NCT04381611 |
|
|
18 |
Aqueous Humor Dynamics and Biometric Parameters in Eyes of Children |
Recruiting |
NCT01290588 |
|
|
19 |
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma |
Active, not recruiting |
NCT03016156 |
|
|
20 |
Histopathological Examination of Iris Tissue in Primary Congenital Glaucoma |
Not yet recruiting |
NCT04079725 |
|
|
|